Immunomodulatory effects of Bacillus firmus on mouse peritoneal cells in vitro
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
17004658
DOI
10.1007/bf02932130
Knihovny.cz E-resources
- MeSH
- Macrophage Activation * MeSH
- Bacillus immunology MeSH
- Cell Culture Techniques methods MeSH
- Cytokines immunology metabolism MeSH
- Lipopolysaccharides pharmacology MeSH
- Mice, Inbred BALB C MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Organic Chemicals pharmacology MeSH
- Nitric Oxide metabolism MeSH
- Peritoneal Cavity cytology MeSH
- Immunity, Innate MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Cytokines MeSH
- Lipopolysaccharides MeSH
- Nocardia delipidated cell mitogen MeSH Browser
- Organic Chemicals MeSH
- Nitric Oxide MeSH
The effect of nonpathogenic G+ bacterium B. firmus (BF) on stimulation of mouse peritoneal cells in vitro was evaluated by testing nitric-oxide-synthesis induction and cytokine formation. The reactivity was compared of peritoneal cells from two inbred mouse strains, C57B1/6 and BALB/c, which differ in their immunological reactivity. Peritoneal macrophages from C57B1/6 produced more nitric oxide after a 1-d cultivation with inactivated BF than those of BALB/c mice. In both strains, production can be further increased by adding exogenous IFN-gamma to the culture. There were no significant differences between peritoneal cells of these two mouse strains in cytokine production after optimal in vitro stimulation with BF. BF effectively activated peritoneal cells for the production of TNF-alpha, IL-1beta and IL-10, delipidated bacterium (DBF) being more efficient than BF in induction of IL-10 and TNF-alpha. On the other hand, BF had only small effect on IFN-gamma production and no detectable effect on IL-12 production. Macrophage activation by BF/DBF can represent one of the mechanisms responsible for previously described immunomodulatory activity of BF.
See more in PubMed
Biochemistry. 1988 Nov 29;27(24):8706-11 PubMed
Biomed Pharmacother. 1986;40(10):392-8 PubMed
J Immunol. 1996 Feb 1;156(3):1196-206 PubMed
J Exp Med. 1997 Dec 1;186(11):1819-29 PubMed
Immunol Lett. 2001 May 1;77(1):39-45 PubMed
Folia Microbiol (Praha). 1995;40(4):413-6 PubMed
Folia Microbiol (Praha). 2004;49(6):737-44 PubMed
Folia Microbiol (Praha). 2003;48(3):427-34 PubMed
Pharmacogenetics. 2000 Aug;10(6):493-501 PubMed
Int J Immunopharmacol. 1998 Jul;20(7):359-68 PubMed
J Immunol. 2000 Jun 15;164(12):6166-73 PubMed
J Exp Med. 1997 Jun 2;185(11):1977-85 PubMed
Immunol Lett. 2005 Mar 15;97(2):251-9 PubMed
Folia Microbiol (Praha). 1994;39(6):501-4 PubMed
Folia Microbiol (Praha). 2002;47(2):193-7 PubMed
Folia Microbiol (Praha). 2006;51(2):154-6 PubMed
Folia Biol (Praha). 1993;39(5):243-9 PubMed
Crit Rev Oncol Hematol. 2002 Nov;44(2):143-61 PubMed
Folia Microbiol (Praha). 1994;39(2):147-51 PubMed
Ann N Y Acad Sci. 1996 Oct 31;795:1-12 PubMed
Folia Microbiol (Praha). 1992;37(6):455-60 PubMed
J Immunol. 1985 Nov;135(5):3277-83 PubMed
Folia Microbiol (Praha). 2005;50(3):247-53 PubMed
Immunol Lett. 1998 Dec;64(2-3):161-6 PubMed
Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus
